Head-To-Head Comparison: Athersys (NASDAQ:ATHX) vs. Mawson Infrastructure Group (OTCMKTS:WIZP)

Valuation & Earnings

This table compares Athersys and Mawson Infrastructure Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146,000.00	0.00	-$72.53 million	($2.03)	N/A
Mawson Infrastructure Group	N/A	N/A	-$3.45 million	($0.33)	-2.34

Mawson Infrastructure Group has lower revenue, but higher earnings than Athersys. Mawson Infrastructure Group is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Athersys and Mawson Infrastructure Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Mawson Infrastructure Group	N/A	N/A	-85.32%

Volatility and Risk

Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Comparatively, Mawson Infrastructure Group has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Institutional & Insider Ownership

19.4% of Athersys shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

About Mawson Infrastructure Group

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia.